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Summary
Objectives: This study has been conducted to assess the efficacy and safety of
topiramate in refractory epilepsies in infants and young children.
Methods: A prospective clinical trial was performed in three tertiary care hospitals,
on 47 children aged 6—60months with refractory epilepsy. Topiramate was added to at
least two baseline anti-epileptic drugs. The efficacy was rated according to seizure
type, frequency and duration.
Results: Children with refractory epilepsy were classified according to their clinical,
neuro-imaging, and neurophysiological profile into infantile spasms (IS) (9 cases, 19%),
Lennox—Gastaut syndrome (LGS) (25 cases, 53%) and other epilepsies (13 cases, 28%).
Children were also classified into cryptogenic and symptomatic epilepsy. Topiramate
was introduced as add-on therapy in a daily dose of 1 mg/kg/day for 2 weeks, followed
by increments of 1—3 mg/kg/day at 2-week intervals, up to a maximum of 10 mg/kg/
day. After a minimum treatment period of 6 months, 28 (60%) of the children had a
satisfactory response (completely seizure free, or more than a 50% seizure reduction).
The remaining 19 children (40%) had an unsatisfactory response (50% or less reduction
in seizure frequency, no change or increased seizure frequency).
Topiramate appeared to be equally effective in infantile spasms, Lennox—Gastaut
syndrome and children with other types of epilepsy, with no significant difference
between those with a satisfactory and an unsatisfactory response ( p = 0.089). There
was also no significant difference in response between patients with cryptogenic and
symptomatic epilepsy ( p = 0.360).
Mild to moderate adverse effects, mainly somnolence, anorexia and nervousness,
were present in 25 (53%) of children. One of the children developed hypothyroidism.* Corresponding author. Tel.: +962 795600420; fax: +962 65515598.
E-mail address: daoud@just.edu.jo (A.S. Daoud).
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Topiramate is a novel antiepileptic drug (AED) that
acts by blocking sodium channels, enhancing GABA-
induced influx of chloride, and inhibiting kainite/
AMPA glutamate receptors.1—3
The clinical efficacy and safety of topiramate has
been thoroughly evaluated in adults. It has been
shown to be effective as an adjunctive therapy for
multiple seizure types including localization-related
and primary generalized seizures.4—6
Recent reports have demonstrated the efficacy of
topiramate in school-aged and older children with
generalized and partial epilepsy.7—10 Topiramate is
also effective in the management of Lennox—Gas-
taut syndrome (LGS) and infantile spasms (IS).11—16
There are only a few reports regarding the effec-
tiveness of topiramate in infants and young pre-
school epileptic children. We therefore designed
this prospective multi-center study to assess the
safety and effectiveness of topiramate in different
types of epilepsy in children between the ages of 6
and 60 months.
Methods
This study was designed to assess prospectively the
efficacy of topiramate in infants and young children
with refractory epilepsy. A consecutive series of 47
children (27 boys and 20 girls), aged between 6 and
60 months, with refractory epilepsy (defined as
recurrent seizures that have failed to respond to
trials of at least two AEDs used in combination,
despite using the maximum dosage, or dosage
resulting in therapeutic drug levels) was identified
between January and December 2002. The children
were recruited from three tertiary hospitals in
Jordan, King Abdullah University Hospital and Prin-
cess Rahmah Teaching Hospital in the north and King
Hussain Medical Center in Amman. The ethical
committees of the three hospitals approved the
study.
Patients were selected according to the following
criteria: (i) age between 6 months and 5 years; (ii)
refractory epilepsy; (iii) currently on at least two
AEDs; (iv) absence of progressive neurological dis-ease. Electroencephalograph (EEG) and computer-
ized tomography or magnetic resonance imaging
were performed on all patients.
Using seizure diaries, parents or caregivers were
asked to record the frequency, type and duration of
all seizures. For those with frequent spasms, and
absences which were difficult to count, parents
were asked to record on a weekly basis the esti-
mated percentage change in seizure frequency, the
options being completely seizure free, >50%
improvement, no change, <50% improvement,
and worsening. Financial restrictions precluded
repetition of the EEG.
Seizures were classified into 3 categories: (i) IS
based on typical clinical and EEG features (ii) LGS
based on clinical (the presence of mixed seizure
patterns with some degree of developmental delay
or intellectual disability) and EEG (a typical EEG
pattern of slow spike wave discharge) features, and
(iii) other epilepsies when the first two were
excluded. Seizures were also classified by etiology
into cryptogenic and symptomatic, five of the nine
children with IS having tuberose sclerosis.
After obtaining informed consent, topiramate
was started twice daily in a total daily dose of
1 mg/kg followed by 2-weekly increments of 1—
3 mg/kg/day until the minimum effective dose
was reached (achieved a seizure free outcome),
up to a maximum dose of 10 mg/kg at all ages,
unless the child was unable to tolerate it.
The 47 children included in the study were fol-
lowed up for a mean period of 6 months (range 3—10
months). Side effects, blood levels of the concomi-
tant AEDs, liver profiles, EEGs, renal ultrasound and
eye examination were monitored in all children. We
had no facilities to check topiramate blood levels.
Therapeutic responses were recorded as satisfac-
tory if there was a complete remission (seizure free)
or more than a 50% seizure reduction, and unsatis-
factory if there was a seizure reduction of 50% or
less, unmodified seizures, or worsening of seizures.
Patients were asked to attend hospital monthly to
be examined for possible side effects, or earlier if
any problems arose. The collected data were ana-
lyzed using Epi Info version 6, and differences
between groups were examined by Fisher’s exact
test.Conclusion: Although the long term safety and possible adverse effects of topiramate
have not been fully established in infants and young children, this study has shown
that it is a useful option for children with frequent seizures unresponsive to standard
anti-epileptic drugs.
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Table 1 Demographic and baseline characteristics of
patients receiving topiramate (n = 47).
Attribute Number and percentage
Age (months)
Range 6—60
Mean 33
Gender
Boys 27 (57%)
Girls 20 (43%)
Epilepsy classifications
Symptomatic 15 (32%)
Cryptogenic 32 (68%)
Infantile spasm 9 (19%)
Lennox—Gastaut 25 (53%)
Others 13 (28%)
Number of background AEDs
Two AEDs 32
More than two AEDs 15
Table 3 Adverse effects observed during treatment
with topiramate (n = 25).
Side effects (25 patients) Number
of patients
Percent
Somnolence 13 28
Poor appetite 11 23
Nervousness, irritability
and agitation
11 23
Fatigue 9 19
Abdominal pain 9 19
Headache 5 11
Dizziness 5 11
Worsened seizures frequency 4 9
Psychomotor slowing 4 9
Weight loss 2 4
Visual complain 2 4
Memory complain 2 4
Hypothyroidism 1 2Results
Forty-seven children entered the study. Their demo-
graphic characteristics, diagnoses and seizure clas-
sifications are detailed in Table 1.
The response to topiramate is detailed in Table 2,
with 60% of the children showing a satisfactory
response. Topiramate was discontinued because of
side effects in 15 children, because of worsening
seizure frequency in 4 (9%), a significant weight loss
in 2 (4%), and lack of response in 9 (19%). Although
other epilepsies appeared to respond better than
LGS to topiramate, the difference was not signifi-
cant (Fisher’s exact test p = 0.077), nor was any
other differences between groups.
The response of LGS children to topiramate was
substantial as 20% had complete remission and
another 32% had good response with marked reduc-
tion (>50%) in the frequency of their seizures. Four 9
infants with IS became either seizure free or
achievedmore than a 50% reduction in their seizuresTable 2 Responses to topiramate according to the clinical
Response LGS
(n = 25)
IS
(n = 9)
Othe
(n = 1
Total remission 5 2 2
>50% improvement 8 2 9
Total satisfactory 13 4 11
50% improvement 3 2 1
No response 6 2 1
Worse 3 1 0
Total unsatisfactory 12 5 2frequency, three of them with tuberous sclerosis. In
the 13 children with other epilepsies, eight with
partial and five with generalized epilepsy, the
response to topiramate was encouraging; two
became seizure free and nine achieved>50% reduc-
tion in seizure frequency.
Side effects to topiramate are detailed in Table 3
and were found in 25 (53%) of the patients. The most
common side effect was a decrease in appetite and
somnolence. One of the patients developed
hypothyroidism during the introduction of topira-
mate. Topiramate had to be withdrawn from four
(9%) patients because of worsening seizure fre-
quency and from another two (4%) because of pro-
gressive weight loss.Discussion
This study shows that topiramate is effective and
well tolerated in infants and young children with
refractory epilepsy. The response is worthwhile intypes of epilepsy.
rs
3)
Total
(n = 47)
Cryptogenic
(n = 32)
Symptomatic
(n = 15)
9 7 2
19 14 5
28 21 7
6 3 3
9 6 3
4 2 2
19 11 8
462 S. Al Ajlouni et al.all types of epilepsy, with no significant difference
between different clinical types or between crypto-
genic and secondary epilepsies.
Similar findings haves reported by Hassan et al.
who reported that 34% of children with intractable
seizures become seizure free and 39% achieved more
than a 50% reduction in seizure frequency.17 Ritter
et al. reported similar findings in childrenwithpartial
epilepsy, with>50% reduction in symptom frequency
in 57%, 14% becoming seizure-free.18 In children and
young adults with refractory partial epilepsy, Cop-
pola et al. achieved seizure free status in 20% and a
50% reduction in seizure frequency in 45%.8 Biton
et al. also reported a substantial response in children
with primary generalized epilepsy, 46% having >50%
reduction in their seizure frequency compared to the
17% in the placebo control group.4
LGS is notoriously difficult to treat, and the
response of this group to topiramate was remark-
able, 60% achieving a satisfactory response. Sach-
deo et al. in a randomized double blind study
reported that 30% of LGS had >50% reduction in
their seizure frequency compared to 8% in the pla-
cebo control group.14 Similar to the finding in this
study, Glauser et al., in an open label trial on LGS,
reported that 15% had no more drop attacks and 55%
had >50% reduction of their seizure frequency.19
Coppola et al. and Alva Moncayo et al. also reported
a good response to topiramate in LGS.15,16
The optimal treatment for IS remains controver-
sial. First-line therapies include adrenocortico-
trophic hormone, steroids and vigabatrin. The
infants with IS in this study had failed to respond
to these medications before topiramate was added,
and we achieved a satisfactory response in four of
our nine cases. Glauser et al. reported that 45% of
his infants with IS become spasm free with topir-
amate, and concluded that topiramate was a pro-
mising drug for the treatment of IS.11 Thiji et al. and
Watemberg also reported a good response to topir-
amate in children with IS who failed to respond to
standard therapy.12,13 Recent reports concerning
the efficacy of topiramate in children with intract-
able epilepsies included infants and children with IS
and LGS. In those reports topiramate therapy was
found to be uniformly efficacious and well tolerated
in a variety of syndromes although data for infants
with IS were not analyzed separately.7,8,17,20
In children with partial and generalized refrac-
tory epilepsy, there was a satisfactory response to
topiramate in 11 of our 13 cases. Previous reports
have also shown a good response.7—10,17,20
Based on the experience of others, the maximum
dosage of topiramate did not exceed 10 mg/kg/
day.7—17 Preliminary data on the pharmacokinetics
of topiramate in infants and young children suggestthat clearance is linear, with a higher plasma clear-
ance than that reported from older children and
adults.21 It is also recommended that in younger
children dosage be adjusted according to response
rather than using the absolute topiramate dose. It is
therefore possible that higher doses (>10 mg/kg/
day) may prove to be more effective in the future.21
As shown in Table 3, most of the side effects of
topiramate were minor and the drug was well toler-
ated. Side effects were noted in 53% of the patients,
the most common being somnolence, decreased
appetite and behavioral changes. Renal stones were
not encountered, although as a precaution routine
renal ultrasoundexaminationswere performedevery
6months onall patients.Most of the side effectswere
transient, particularly the somnolence and
decreased appetite, which resolved spontaneously
or with dose reduction. Nevertheless, topiramate
had to be withdrawn in 13% because of seizure wor-
sening and progressive weight loss.
The frequency of side effects in our study is
similar to that reported by Ritter et al., who
reported that 6% of children discontinued topira-
mate because of adverse effects and 13% discon-
tinued because of inadequate seizure control.
Glauser et al. reported that 71% of their children
were continuing topiramate therapy at the last
visit.18,19 Sachdeo et al. reported that when a lower
target dose was used (6 mg/kg/day), no patient
discontinued topiramate due to adverse events
but despite using this lower target dose, 20% of
their patients also had weight loss.14 In comparison
with other studies, relatively fewer cognitive side
effects (psychomotor delay) have been found. This
is likely to be the result of the slow rate of drug
introduction (cognitive side effects are reported to
be more common with rapid dose titration22) and
the policy of using the minimum effective dose.
Takeoka et al. reported mild metabolic acidosis
(decreased serum bicarbonate) in children on topir-
amate, presumably related to carbonic anhydrase
inhibition, and caution was recommended when
topiramate is used in children with conditions that
may predispose to acidosis or poor weight gain.23 We
did not routinely screen acid-base balance in our
patients. Topiramate therapy had recently been
reported to be associated with glaucoma24 and we
performed routine examinations on all our patients
at 6-monthly intervals. Two children in our series
had visual complaints and were referred to ophthal-
mologist; they did not have glaucoma. One of our
children with LGS developed hypothyroidism. This
child was diagnosed with hypothyroidism at the age
of 40 months because of psychomotor retardation, 9
months after adding topiramate. Before the intro-
duction of topiramate he received carbamazepine
Efficacy of topiramate in young children 463for 4 months at the age of 15 months then changed
to valproate and clonazepam until the age of 31
months when topiramate was added. The rela-
tionship between hypothyroidism and topiramate
therapy in this child is uncertain, as he was on other
AEDs and baseline thyroid function tests were not
available.
Although the long term safety and possible
adverse effects of topiramate have not been fully
established in infant and young children, our study
confirms that topiramate is a valuable option for
children with high seizure frequency unresponsive
to standard AEDs.References
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